🎉 M&A multiples are live!
Check it out!

Humacyte Valuation Multiples

Discover revenue and EBITDA valuation multiples for Humacyte and similar public comparables like Cynata Therapeutics, Mesoblast, and Aroa Biosurgery.

Humacyte Overview

About Humacyte

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.


Founded

2020

HQ

United States of America
Employees

220

Website

humacyte.com

Financials

LTM Revenue $2.4M

LTM EBITDA n/a

EV

$203M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Humacyte Financials

Humacyte has a last 12-month revenue of $2.4M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Humacyte achieved revenue of n/a and an EBITDA of -$132M.

Humacyte expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Humacyte valuation multiples based on analyst estimates

Humacyte P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$96.5M -$132M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$12.0M -$111M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Humacyte Stock Performance

As of April 15, 2025, Humacyte's stock price is $1.

Humacyte has current market cap of $231M, and EV of $203M.

See Humacyte trading valuation data

Humacyte Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$203M $231M XXX XXX XXX XXX $-1.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Humacyte Valuation Multiples

As of April 15, 2025, Humacyte has market cap of $231M and EV of $203M.

Humacyte's trades at 83.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Humacyte's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Humacyte and 10K+ public comps

Humacyte Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $203M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -1.5x XXX XXX XXX
P/E -1.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -2.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Humacyte Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Humacyte Valuation Multiples

Humacyte's NTM/LTM revenue growth is 1119%

Humacyte's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.5M for the same period.

Over next 12 months, Humacyte's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Humacyte's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Humacyte and other 10K+ public comps

Humacyte Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 37% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Humacyte Public Comps

See public comps and valuation multiples for Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Lineage Cell Therapeutics XXX XXX XXX XXX XXX XXX
Arovella Therapeutics XXX XXX XXX XXX XXX XXX
Aroa Biosurgery XXX XXX XXX XXX XXX XXX
Cynata Therapeutics XXX XXX XXX XXX XXX XXX
Mesoblast XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Humacyte M&A and Investment Activity

Humacyte acquired  XXX companies to date.

Last acquisition by Humacyte was  XXXXXXXX, XXXXX XXXXX XXXXXX . Humacyte acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Humacyte

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Humacyte

When was Humacyte founded? Humacyte was founded in 2020.
Where is Humacyte headquartered? Humacyte is headquartered in United States of America.
How many employees does Humacyte have? As of today, Humacyte has 220 employees.
Who is the CEO of Humacyte? Humacyte's CEO is Dr. Laura E. Niklason.
Is Humacyte publicy listed? Yes, Humacyte is a public company listed on NAS.
What is the stock symbol of Humacyte? Humacyte trades under HUMA ticker.
When did Humacyte go public? Humacyte went public in 2021.
Who are competitors of Humacyte? Similar companies to Humacyte include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics.
What is the current market cap of Humacyte? Humacyte's current market cap is $231M
What is the current revenue of Humacyte? Humacyte's last 12-month revenue is $2.4M.
What is the current EV/Revenue multiple of Humacyte? Current revenue multiple of Humacyte is 83.5x.
Is Humacyte profitable? Yes, Humacyte is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.